UCB SA

Pharmaceuticals
Belgium
Earnings Per Share Growth (%)195.45%
Cost of Goods Sold (US$ Millions)$1,260
Current Liabilities (US$ Millions)$3,334
Total Assets (US$ Millions)$3,091
Long Term Debt$1,726
Return on Equity12.46%
Revenue (US$ Millions)$4,222
Total Company Assets$11,933
Revenue Growth (%)15.91%
Net Income (US$ Millions)$679
Earnings Per Share (US$)$195.45
Total Equity (US$ Millions)$6,178
Profit Margin (%)16.07%
Debt To Equity Ratio (%)0.28%
Inventory Turnover$616